Literature DB >> 2551760

Mechanism of IGF-I-stimulated glucose transport in human adipocytes. Demonstration of specific IGF-I receptors not involved in stimulation of glucose transport.

M K Sinha1, C Buchanan, N Leggett, L Martin, P G Khazanie, R Dimarchi, W J Pories, J F Caro.   

Abstract

We demonstrate the presence of specific insulinlike growth factor I (IGF-I) receptors in human adipocytes. Competition studies with 125I-labeled IGF-I and unlabeled IGF-I, IGF-II, and insulin showed the specificity of 125I-IGF-I binding to the IGF-I receptors in adipocytes, membranes, and partially purified detergent-solubilized extracts. The monoclonal antibody to the IGF-I receptor (alpha-IR3) inhibits 125I-IGF-I binding and immunoprecipitates the IGF-I receptor. In addition, the alpha-subunit of IGF-I receptor is approximately 10,000 Mr larger than the alpha-subunit of insulin receptor, and IGF-I stimulates phosphorylation of the beta-subunit of the IGF-I receptor. IGF-I stimulates basal glucose transport in human adipocytes, but the concentrations of IGF-I required for half-maximal and maximal stimulation of glucose transport are 800- and 1000-fold greater than that of insulin. The possibility of IGF-I stimulating glucose transport by interacting predominantly with insulin receptors is suggested by data showing that 1) IGF-I competes with insulin-binding sites, 2) there is a lack of an additive effect with IGF-I and insulin in stimulating glucose transport, 3) alpha-IR3, which specifically inhibits IGF-I binding, does not inhibit IGF-I or insulin-stimulated glucose transport, 4) insulin-receptor antibody MA-10 inhibits IGF-I and insulin-stimulated glucose transport, and 5) IGF-I stimulates insulin-receptor autophosphorylation, although its effect is markedly decreased compared with insulin. In summary, human adipocytes possess specific IGF-I receptors. However, IGF-I stimulates glucose transport predominantly by interacting with the insulin receptor.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2551760     DOI: 10.2337/diab.38.10.1217

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  11 in total

Review 1.  Diabetic nephropathy. Its relationship to hypertension and means of pharmacological intervention.

Authors:  T Baba; S Neugebauer; T Watanabe
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

2.  In vivo metabolic action of insulin-like growth factor I in adult rats.

Authors:  F Schmitz; H Hartmann; F Stümpel; W Creutzfeldt
Journal:  Diabetologia       Date:  1991-03       Impact factor: 10.122

3.  Involvement of the Ras/extracellular signal-regulated kinase signalling pathway in the regulation of ERCC-1 mRNA levels by insulin.

Authors:  W Lee-Kwon; D Park; M Bernier
Journal:  Biochem J       Date:  1998-04-15       Impact factor: 3.857

4.  Effects of insulin-like growth factor I on the rates of glucose transport and utilization in rat skeletal muscle in vitro.

Authors:  G Dimitriadis; M Parry-Billings; S Bevan; D Dunger; T Piva; U Krause; G Wegener; E A Newsholme
Journal:  Biochem J       Date:  1992-07-01       Impact factor: 3.857

Review 5.  Advances in the treatment of diabetes mellitus in the elderly. Development of insulin analogues.

Authors:  B J Hoogwerf; A Mehta; S Reddy
Journal:  Drugs Aging       Date:  1996-12       Impact factor: 3.923

6.  Insulin-like growth factor-I improves glucose and lipid metabolism in type 2 diabetes mellitus.

Authors:  P D Zenobi; S E Jaeggi-Groisman; W F Riesen; M E Røder; E R Froesch
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

Review 7.  The link between insulin resistance and hypertension. Effects of antihypertensive and antihyperlipidaemic drugs on insulin sensitivity.

Authors:  T Baba; S Neugebauer
Journal:  Drugs       Date:  1994-03       Impact factor: 9.546

8.  Comparison of the effects of human recombinant insulin-like growth factor I and insulin on plasma amino acid concentrations and leucine kinetics in humans.

Authors:  M Giordano; P Castellino; C A Carroll; R A DeFronzo
Journal:  Diabetologia       Date:  1995-06       Impact factor: 10.122

9.  Comparison of the metabolic effects of recombinant human insulin-like growth factor-I and insulin. Dose-response relationships in healthy young and middle-aged adults.

Authors:  S D Boulware; W V Tamborlane; N J Rennert; N Gesundheit; R S Sherwin
Journal:  J Clin Invest       Date:  1994-03       Impact factor: 14.808

10.  A low dose euglycemic infusion of recombinant human insulin-like growth factor I rapidly suppresses fasting-enhanced pulsatile growth hormone secretion in humans.

Authors:  M L Hartman; P E Clayton; M L Johnson; A Celniker; A J Perlman; K G Alberti; M O Thorner
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.